Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi

Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ;